Chemed (NYSE:CHE – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 23.550-23.800 for the period, compared to the consensus estimate of 23.210. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.55-23.80 EPS.
Chemed Price Performance
NYSE CHE traded down $6.51 during trading hours on Thursday, hitting $540.97. The company’s stock had a trading volume of 221,404 shares, compared to its average volume of 85,353. Chemed has a 12 month low of $492.84 and a 12 month high of $654.62. The company’s 50 day simple moving average is $544.12 and its two-hundred day simple moving average is $583.59. The company has a market cap of $8.19 billion, a P/E ratio of 30.44, a price-to-earnings-growth ratio of 2.23 and a beta of 0.43.
Chemed (NYSE:CHE – Get Free Report) last announced its earnings results on Wednesday, July 24th. The company reported $5.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.59 by ($0.12). The firm had revenue of $595.88 million during the quarter, compared to analysts’ expectations of $599.20 million. Chemed had a return on equity of 30.52% and a net margin of 12.36%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the previous year, the business posted $4.71 earnings per share. As a group, research analysts predict that Chemed will post 21.54 earnings per share for the current fiscal year.
Chemed Announces Dividend
Wall Street Analyst Weigh In
Several brokerages have issued reports on CHE. Royal Bank of Canada dropped their target price on Chemed from $712.00 to $697.00 and set an outperform rating on the stock in a research report on Tuesday, May 21st. StockNews.com raised Chemed from a hold rating to a buy rating in a research report on Saturday, May 4th.
Get Our Latest Analysis on CHE
Insider Activity
In other news, Director Patrick P. Grace sold 284 shares of Chemed stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total transaction of $153,638.32. Following the transaction, the director now directly owns 3,270 shares of the company’s stock, valued at approximately $1,769,004.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $567.54, for a total value of $2,270,160.00. Following the transaction, the chief executive officer now directly owns 108,549 shares of the company’s stock, valued at approximately $61,605,899.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Patrick P. Grace sold 284 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total value of $153,638.32. Following the completion of the transaction, the director now directly owns 3,270 shares in the company, valued at $1,769,004.60. The disclosure for this sale can be found here. Insiders have sold a total of 5,784 shares of company stock valued at $3,240,053 in the last ninety days. Corporate insiders own 3.32% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- Using the MarketBeat Dividend Yield Calculator
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How to Calculate Inflation Rate
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.